首页> 外文期刊>Bone marrow transplantation >Early lymphocyte recovery post-allogeneic hematopoietic stem cell transplantation is associated with significant graft-versus-leukemia effect without increase in graft-versus-host disease in pediatric acute lymphoblastic leukemia.
【24h】

Early lymphocyte recovery post-allogeneic hematopoietic stem cell transplantation is associated with significant graft-versus-leukemia effect without increase in graft-versus-host disease in pediatric acute lymphoblastic leukemia.

机译:同种异体造血干细胞移植后的早期淋巴细胞恢复与显着的移植物抗白血病作用相关,而在小儿急性淋巴细胞白血病中移植物抗宿主疾病没有增加。

获取原文
获取原文并翻译 | 示例
           

摘要

To study the effect of early lymphocyte recovery post-allogeneic hematopoietic stem cell transplantation (HSCT) on outcome in pediatric ALL, we reviewed 136 consecutive pediatric patients with ALL who received allogeneic HSCT between 1994 and 2005 at the Hospital for Sick Children, Toronto, Canada. Patients with an absolute lymphocyte count (ALC) <0.3 x 10(9) per liter at day 21 (n=104) had more than five times risk of relapse compared to those with ALC >0.3 x 10(9) per liter (n=32) (hazard ratio (HR) 5.3; P=0.002) and had inferior 3-year event-free survival, (EFS), 0.42 (95% confidence interval (CI) 0.32, 0.51) compared to 0.66 (95% CI 0.48, 0.82; P=0.02). Similarly, patients with an ALC <0.3 x 10(9) per liter (n=48) at day 30 were more than twice as likely to relapse compared to those with an ALC >0.3 x 10(9) per liter (n=88) (HR 2.2; P=0.01) and had an inferior 3-year EFS, 0.30 (95% CI 0.18, 0.45) compared to 0.57 (95% CI 0.46, 0.68; P=0.0001). Interestingly, increasing ALC at days 21 and 30 was notassociated with increased incidence of acute or chronic GVHD or transplant-related mortality (TRM). Early lymphocyte recovery post-HSCT is associated with a significant GVL without increase in GVHD.
机译:为了研究异基因造血干细胞移植(HSCT)后早期淋巴细胞恢复对小儿ALL结局的影响,我们回顾了1994年至2005年之间在加拿大多伦多市儿童病医院接受异基因HSCT的136例连续小儿ALL患者。第21天(n = 104),每升绝对淋巴细胞计数(ALC)<0.3 x 10(9)的患者与每升ALC> 0.3 x 10(9)的患者相比,复发风险高五倍以上(n = 32)(危险比(HR)5.3; P = 0.002),且3年无事件生存率(EFS)为0.42(95%置信区间(CI)0.32,0.51),而0.66(95%CI) 0.48,0.82; P = 0.02)。同样,第30天ALC <0.3 x 10(9)/升(n = 48)的患者复发率是ALC> 0.3 x 10(9)/升(n = 88)的两倍以上。 )(HR 2.2; P = 0.01),三年期EFS较低,为0.30(95%CI 0.18,0.45),而0.57(95%CI 0.46,0.68; P = 0.0001)。有趣的是,第21天和第30天的ALC升高与急性或慢性GVHD发生率或与移植相关的死亡率(TRM)升高无关。 HSCT后的早期淋巴细胞恢复与显着的GVL相关,而GVHD没有增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号